Extended Release Liposomal Bupivacaine Injection (Exparel) for Early Postoperative Pain Control Following Pharyngoplasty
Related Experiment Video
Updated: Feb 14, 2026

Acupoint Needle-Embedding Combined with Ironing Therapy for Postoperative Pain After Anal Surgery
Published on: June 23, 2023
Kristopher M Day1, Narayanan M Nair, Devan Griner
1Department of Plastic Surgery, University of Tennessee College of Medicine, Chattanooga, TN.
Insights
Liposomal bupivacaine (LB) offers improved pain control in pediatric pharyngoplasty patients. This long-acting anesthetic led to earlier oral intake, reduced opioid use, and shorter hospital stays.
Area of Science:
- Anesthesiology
- Pediatric Surgery
- Pain Management
Background:
- Liposomal bupivacaine (LB) is a long-acting local anesthetic.
- Previous studies suggest LB can decrease postoperative pain.
- This study evaluates the safety and efficacy of LB in pediatric pharyngoplasty.
Purpose of the Study:
- To assess the effectiveness of liposomal bupivacaine in pediatric patients undergoing pharyngoplasty.
- To compare pain scores, oral intake, opioid requirements, and hospitalization duration between LB and traditional anesthetics.
Main Methods:
- Retrospective case-control study of pediatric pharyngoplasty patients (March 2010-June 2016).
- Treatment group received LB plus bupivacaine and epinephrine.
- Control group received lidocaine and epinephrine.
Main Results:
- LB group showed significantly lower initial pain scores.
- The LB group tolerated oral intake earlier and in greater volumes.
- Patients receiving LB required fewer opioids and had shorter hospital stays.
Conclusions:
- Liposomal bupivacaine is safe and effective for pediatric pharyngoplasty.
- LB use is associated with reduced opioid consumption.
- LB facilitates earlier oral intake and shorter hospitalizations in pediatric surgical patients.
Background:
Liposomal bupivacaine (LB, Exparel) is a long-acting local anesthetic reported to decrease postoperative. The authors demonstrate the first safe use of LB in pediatric patients with improved pain control following pharyngoplasty.
Methods:
Retrospective case-control of all the patients who underwent pharyngoplasty at a tertiary craniofacial center from March 2010 to June 2016. Treatment group (TG) administered 1.3% LB and 0.5% bupivacaine and 1:200,000 epinephrine. Control group (CG) administered 0.5% lidocaine with 1:200,000 epinephrine. Pain scores, oral intake, opioids administered, and duration of hospitalization were measured.
Results:
Sixty patients (30 males, 30 females; average age 6.2 ± 2.4 years, weight 20.9 ± 6.8 kg) were evenly divided into a TG that received 3.5 ± 2.1 mL (2.6 ± 1.9 mg/kg) LB and 2.0 ± 2.3 mL 0.5% bupivacaine and a CG that received 2.7 ± 3.2 mL lidocaine. Treatment group patients had lower initial face, legs, activity, cry, consolability pain scale scores (0.1 ± 0.55/10, P = 0.0049; CG 4.5 ± 1.1/10, P = 0.00061) and no significant inpatient pain score difference 0 to 36 hours postoperative (P = 0.32-0.53). Oral intake was tolerated 0.21 ± 0.12 days (P < 0.0001) earlier by the TG and with greater first 24-hour average volume (377.6 ± 351.9 cc, P < 0.0001). Treatment group patients were discharged 1.8 ± 0.87 days (P = 0.00023) earlier and required lower average opioids (15.1 ± 11.2 mg hydrocodone-equivalents) than CG (27.5 ± 19.1 mg hydrocodone-equivalents; P = 0.0017).
Conclusions:
Liposomal bupivacaine is safe in pediatric patients, associated with less opioids, increased and earlier oral intake, and shorter hospital stay.
More Related Videos
Related Concept Videos
Pain
Gravitational Potential Energy for Extended Objects
Energy-releasing Steps of Glycolysis
The first energy-releasing step—the 6th step of glycolysis...
Peripheral Artery Disease V: Postoperative Nursing Management
Analgesia and Pain Management
Modified-Release Drug Delivery Systems: Drug Release Characteristics

